CLASS II ONGOING Drug recall · Reported 24 Sep 2025 · FDA Enforcement Report
bevacizumab (Avastin) Injection, 1.25mg/ Fill) recalled
Fagron Compounding Services is recalling bevacizumab (Avastin) Injection, 1.25mg/ Fill), Sterile Single-Dose Syringe, Fagron, distributed nationwide in the US. The recall was initiated on 29 Aug 2025 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0646-2025
- FDA event ID
- 97540
- Recalling firm
- Fagron Compounding Services, Wichita, KS
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- 29 Aug 2025
- FDA classified
- 12 Sep 2025
- Reported
- 24 Sep 2025
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Sterility
- Drug class
- Injectable & IV Drugs
Timeline
| 29 Aug 2025 | Recall initiated by company | |
| 12 Sep 2025 | Classified by FDA | +14 days |
| 24 Sep 2025 | Published in enforcement report | +12 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack of Assurance of Sterility
A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.
Product as listed by the FDA
bevacizumab (Avastin) Injection, 1.25mg/0.05mL (0.12 mL Fill), Sterile Single-Dose Syringe, Fagron Sterile Services, 8710 E 34th St N. Wichita, KS 67226
Where it was distributed
USA nationwide.
Questions about this recall
Why was it recalled?
Lack of Assurance of Sterility
Which lots are affected?
Lot #: C274-000044756, C274-000044757, Exp 8-30-2025; C274-000044832, C274-000044833, Exp 9-4-2025; C274-000044882, C274-000044883, Exp 9-6-2025, C274-000044972, Exp 9-8-2025; C274-000045004, C274-000045005, Exp 9-18-2025 C274-000045108, exp. date 9-13-2025 C274-000045109, exp. date 9-13-2025 C274-000045136, exp. date 9-14-2025 C274-000045137, exp. date 9-14-2025 C274-000045289, exp. date 9-20-2025 C274-000045290, exp. date 9-20-2025 C274-000045350, exp. date 9-22-2025 C274-000045351, exp. date 9-22-2025 C274-000045387, exp. date 9-25-2025 C274-000045388, exp. date 9-25-2025 C274-000045516, exp. date 9-27-2025 C274-000045517, exp. date 9-27-2025 C274-000045586, exp. date 10-2-2025 C274-000045587, exp. date 10-2-2025 C274-000045676, exp. date 10-4-2025 C274-000045677, exp. date 10-4-2025 C274-000045707, exp. date 10-5-2025 C274-000045708, exp. date 10-5-2025 C274-000045754, exp. date 10-9-2025 C274-000045755, exp. date 10-9-2025 C274-000045840, exp. date 10-11-2025 C274-000045841, exp. date 10-11-2025 C274-000046048, exp. date 10-24-2025 C274-000046049, exp. date 10-24-2025 C274-000046095, exp. date 10-25-2025 C274-000046096, exp. date 10-25-2025 C274-000046122, exp. date 10-26-2025 C274-000046123, exp. date 10-26-2025 C274-000046164, exp. date 10-30-2025 C274-000046165, exp. date 10-30-2025 C274-000046191, exp. date 10-31-2025 C274-000046192, exp. date 10-31-2025 C274-000046240, exp. date 11-1-2025 C274-000046241, exp. date 11-1-2025 C274-000046315, exp. date 11-6-2025 C274-000046316, exp. date 11-6-2025 C274-000046345, exp. date 11-7-2025 C274-000046346, exp. date 11-7-2025 C274-000046515, exp. date 11-14-2025 C274-000046516, exp. date 11-14-2025 C274-000046603, exp. date 11-16-2025 C274-000046657, exp. date 11-20-2025 C274-000047136, exp. date 12-12-2025
Where was it sold?
USA nationwide.
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from Fagron Compounding Services
All 13| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Vancomycin HCL added to, 0.9% Sodium Chloride Injection recalled | Fagron Compounding Services | Sterility | Nationwide |
| Drug | CLASS II | norepinephrine Bitartrate,16mg per 0.9% Sodium Chloride recalled | Fagron Compounding Services | Sterility | Nationwide |
| Drug | CLASS II | norepinephrine Bitartrate, 32mg per 0.9% Sodium Chloride recalled | Fagron Compounding Services | Sterility | Nationwide |
| Drug | CLASS II | Vancomycin HCI added to, 0.9% Sodium Chloride Injection recalled | Fagron Compounding Services | Sterility | Nationwide |
| Drug | CLASS II | Vancomycin HCI added to, 0.9% Sodium Chloride Injection recalled | Fagron Compounding Services | Sterility | Nationwide |
Other Bevacizumab (avastin recalls
All 3| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Bevacizumab (Avastin)1.25mg/, Sterile Injection Single-Dose Syringe recalled | Tailstorm Health | Sterility | Nationwide |
| Drug | CLASS II | Bevacizumab (Avastin) 2.5mg/ PF Inj recalled by Leiter's Pharmacy | Leiter's Pharmacy | Sterility | Nationwide |